Vicebio England United Kingdom

Financing led by new investor TCGX, alongside Goldman Sachs Alternatives, Avoro Ventures and venBio Funding will support and accelerate development of next-generation multivalent respiratory virus vaccines using proprietary Molecular Clamp technology Commenced Phase I clinical study of bivalent vaccine targeting both Respiratory Syncytial Virus (RSV) and Human Metapneumovirus (hMPV) View original content:https://www.prnewswire.co.uk/news-releases/vicebio-announces-100-million-series-b-financing-and-initiation-of-phase-1-clinical-study-of-rsvhmpv-bivalent-vaccine-302254784.html